RetinalGenix Technologies Participates in Premier Investor Conference
RetinalGenix Technologies Inc. OTCQB:RTGN, a forward-thinking company in the ophthalmic field, recently announced its participation at a prestigious investor conference. This event gathers prominent players in the investment community, featuring insights from industry leaders and opportunities to connect with emerging growth companies.
Highlighting Innovative Retinal Imaging Solutions
During the conference, RetinalGenix will showcase its cutting-edge technology, the RetinalCam™, which offers high-resolution, real-time retinal and ocular imaging and monitoring. This advanced device is currently in the prototype phase, offering promising capabilities that may aid in the early detection of conditions that could lead to blindness or systemic diseases.
Focus on Early Detection and Patient Outcomes
RetinalGenix is dedicated to improving patient outcomes by facilitating the detection of early biomarkers. The goals of their ongoing research include ensuring that initial physiological changes are identified in a timely manner, which can significantly improve diagnosis and treatment for various ocular and systemic diseases.
Conference Attendance Schedule and Opportunities
Jerry Katzman, MD, the CEO of RetinalGenix Technologies, plans to attend the conference, where he will be available for one-on-one meetings with interested investors. Meetings are scheduled for March 17 and 18, and attendees are encouraged to reach out to their ROTH representatives or register for this opportunity.
About the Roth Conference
The Roth Conference is known as one of the foremost events for institutional investors in the United States. It features a diverse array of speakers from various industries and offers a unique platform for presenting innovative companies. This year’s event will be held at a premier venue, providing excellent networking opportunities for all attendees.
Innovations in Pharmaco-Genetic Mapping
In addition to the RetinalCam™, RetinalGenix Technologies is also progressing its revolutionary DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ software. This pioneering approach aims to advance the development of new methods and therapeutic products, which could reshape the landscape of precision medicine.
Potential Impact on Disease Prevention
The company’s cutting-edge technologies are designed to detect diseases such as diabetic conditions, Alzheimer's disease, and Parkinson's disease in their early stages. This early intervention capability is crucial for improving patient care and outcomes in these challenging medical areas.
Aiming for Market Readiness
RetinalGenix is on track to complete testing of its devices by the second quarter of the year, with an optimistic outlook for the first sales later in 2025. This timeline reflects the company’s commitment to bringing innovative healthcare solutions to market promptly.
Vision for the Future
By integrating genetic screening, preventative imaging, and drug development, RetinalGenix Technologies aims to emerge as a leader in the realm of personalized medicine. Their holistic approach to patient care is setting new standards in the industry, and their presence at the Roth Conference highlights their vision and commitment to this mission.
Frequently Asked Questions
1. What is the purpose of the Roth Conference for RetinalGenix?
RetinalGenix uses the Roth Conference to present its innovative technologies and connect with potential investors.
2. What technology is RetinalGenix showcasing?
They are showcasing the RetinalCam™, a technology for high-resolution retinal imaging.
3. Who will represent RetinalGenix at the conference?
Dr. Jerry Katzman, the CEO, will be attending and available for meetings.
4. What is unique about RetinalGenix's approach?
RetinalGenix integrates advanced imaging with genetic mapping for better disease detection and treatment.
5. When is RetinalGenix planning to launch its products?
The company is aiming for product sales to begin later in the year following testing completion.
